Table 2.
Clinical and biological features of CLL patients
| TP53-wt (n = 16) | TP53-mut (n = 10) | |
|---|---|---|
| Total, n | Total, n | |
| Age at the diagnosis | ||
| median (range), years | 63 (43–81) | 70 (52–85) |
| Gender | ||
| male | 9 (56%) | 6 (60%) |
| female | 7 (44%) | 4 (40%) |
| Stage | ||
| Binet A | 16 (100%) | 9 (90%) |
| Binet B | 0 (−) | 1 (10%) |
| Binet C | 0 (−) | 0 (−) |
| IGHVa | ||
| Mutated | 16 (100%) | 2 (20%) |
| Unmutated | 0 (−) | 7 (70%) |
| NA | – | 1 (10%) |
| CD38b | ||
| Negative | 16 (100%) | 4 (40%) |
| Positive | 0 (-) | 6 (60%) |
| Cytogenetics | ||
| Favorable | 0 (-) | 2 (20%) |
| Neutral | 16 (100%) | 3 (30%) |
| Unfavorable | 0 (−) | 3 (30%) |
| NA | – | 2 (20%) |
| Follow-up | ||
| Median (range), years | 4 (1–6) | 5 (2–19) |
| Disease progression, requiring treatment during follow-up | 2 (13%) | 7 (70%) |
| TTFT | ||
| Median (range), months | 14 (7–22) | 49 (3–212) |
NA not available
aIGHV sequencing utilized a 2% cutoff to discriminate mutated from unmutated IGHV
bCD38 was determined using a 30% cutoff